AR087485A1 - Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc - Google Patents
Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pcInfo
- Publication number
- AR087485A1 AR087485A1 ARP120102895A ARP120102895A AR087485A1 AR 087485 A1 AR087485 A1 AR 087485A1 AR P120102895 A ARP120102895 A AR P120102895A AR P120102895 A ARP120102895 A AR P120102895A AR 087485 A1 AR087485 A1 AR 087485A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequence
- amino acid
- seq
- acid sequence
- identity
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 abstract 2
- 229950004354 phosphorylcholine Drugs 0.000 abstract 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 1
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 abstract 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 1
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 1
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161521593P | 2011-08-09 | 2011-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087485A1 true AR087485A1 (es) | 2014-03-26 |
Family
ID=46679261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102895A AR087485A1 (es) | 2011-08-09 | 2012-08-08 | Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9803028B2 (enExample) |
| EP (1) | EP2742068B1 (enExample) |
| JP (1) | JP6277125B2 (enExample) |
| KR (1) | KR101947758B1 (enExample) |
| CN (1) | CN104039832B (enExample) |
| AR (1) | AR087485A1 (enExample) |
| AU (1) | AU2012293646B2 (enExample) |
| BR (1) | BR112014002929A8 (enExample) |
| CA (1) | CA2843921A1 (enExample) |
| CY (1) | CY1121950T1 (enExample) |
| DK (1) | DK2742068T3 (enExample) |
| ES (1) | ES2732838T3 (enExample) |
| HK (1) | HK1200852A1 (enExample) |
| HR (1) | HRP20190988T1 (enExample) |
| HU (1) | HUE045163T2 (enExample) |
| LT (1) | LT2742068T (enExample) |
| MX (1) | MX364425B (enExample) |
| PL (1) | PL2742068T3 (enExample) |
| PT (1) | PT2742068T (enExample) |
| RS (1) | RS58986B1 (enExample) |
| RU (1) | RU2654584C2 (enExample) |
| SG (1) | SG2014009344A (enExample) |
| SI (1) | SI2742068T1 (enExample) |
| SM (1) | SMT201900366T1 (enExample) |
| TR (1) | TR201909072T4 (enExample) |
| TW (1) | TWI707873B (enExample) |
| WO (1) | WO2013020995A1 (enExample) |
| ZA (1) | ZA201400665B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012294431B2 (en) | 2011-08-09 | 2017-03-30 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (PC) and/or PC conjugates |
| SI2742068T1 (sl) * | 2011-08-09 | 2019-08-30 | Athera Biotechnologies Ab | Nova protitelesa proti fosforilholinu |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| US20180066262A1 (en) | 2015-03-09 | 2018-03-08 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| EP3314027A4 (en) | 2015-06-29 | 2019-07-03 | Caris Science, Inc. | THERAPEUTIC OLIGONUCLEOTIDES |
| EP3328873B1 (en) | 2015-07-28 | 2025-09-17 | Caris Science, Inc. | Targeted oligonucleotides |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2402664A1 (fr) | 1977-09-07 | 1979-04-06 | Agronomique Inst Nat Rech | Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications |
| US5955584A (en) | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| DE3751182T2 (de) | 1986-08-06 | 1995-10-26 | Scripps Clinic Res | Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden. |
| JPH02188532A (ja) | 1989-01-17 | 1990-07-24 | Otsuka Pharmaceut Co Ltd | リポソームワクチン |
| WO1990012632A1 (en) | 1989-04-19 | 1990-11-01 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids |
| JP3283041B2 (ja) | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
| EP0562020A4 (en) | 1990-12-10 | 1993-11-18 | Alving, Carl L. | A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis |
| RU2014609C1 (ru) * | 1991-06-06 | 1994-06-15 | Московский институт тонкой химической технологии им.М.В.Ломоносова | Способ определения белков, специфичных к фосфорилхолину |
| EP0631624A1 (en) | 1992-03-03 | 1995-01-04 | The Rockefeller University | Receptor complexes with b29 (ig-beta or ig-gamma) and their uses |
| AU5959494A (en) | 1992-12-29 | 1994-07-19 | Entremed, Inc | Vaccines against sterols |
| AU6268894A (en) | 1993-02-22 | 1994-09-14 | Alza Corporation | Compositions for oral delivery of active agents |
| US5455032A (en) | 1993-07-29 | 1995-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Use of phosphocholine hapten conjugates in vaccines |
| AU1159497A (en) | 1996-11-08 | 1998-06-03 | Regents Of The University Of California, The | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| US6375925B1 (en) | 1996-11-08 | 2002-04-23 | The Regents Of The University Of California | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| US6225070B1 (en) | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
| US20040185039A1 (en) | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
| US6300308B1 (en) | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| ES2205853T3 (es) | 1998-07-03 | 2004-05-01 | Athera Biotechnologies Ab | Metodo para diagnosticar la enfermedad cardiovascular y la aterosclerosis precoz. |
| JP2003513027A (ja) | 1999-10-26 | 2003-04-08 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | アテローム性動脈硬化症の診断、結像、治療用の薬剤及びその方法 |
| SE0000855D0 (sv) | 2000-03-15 | 2000-03-15 | Karolinska Innovations Ab | Antigenic composition useful as a vaccine against atherosclerosis |
| AU2001259730A1 (en) | 2000-05-12 | 2001-11-26 | The Regents Of The University Of California | Standardized oxidized ldl assay |
| DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| US20070122419A1 (en) | 2003-04-11 | 2007-05-31 | The Regents Of The University Of California | Methods and compositions for treating atherosclerosis |
| CN1968965B (zh) | 2004-04-15 | 2015-12-16 | 阿瑟拉生物技术公司 | 磷酸胆碱偶联物和相应抗体 |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| WO2006110831A2 (en) | 2005-04-12 | 2006-10-19 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
| US20080311122A1 (en) | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
| US20090258005A1 (en) | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
| JP5122908B2 (ja) | 2007-10-17 | 2013-01-16 | 日泉化学株式会社 | 自動車の内装用部材の取り付け構造 |
| US20110206679A1 (en) * | 2008-07-07 | 2011-08-25 | Athera Biotechnologies Ab | New Therapeutic and Diagnostic Methods for Alzheimer's Disease |
| WO2012010291A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| KR102502293B1 (ko) * | 2011-01-06 | 2023-02-21 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| SI2742068T1 (sl) * | 2011-08-09 | 2019-08-30 | Athera Biotechnologies Ab | Nova protitelesa proti fosforilholinu |
| AU2012294431B2 (en) | 2011-08-09 | 2017-03-30 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (PC) and/or PC conjugates |
-
2012
- 2012-08-08 SI SI201231604T patent/SI2742068T1/sl unknown
- 2012-08-08 PL PL12747915T patent/PL2742068T3/pl unknown
- 2012-08-08 DK DK12747915.2T patent/DK2742068T3/da active
- 2012-08-08 HU HUE12747915A patent/HUE045163T2/hu unknown
- 2012-08-08 TR TR2019/09072T patent/TR201909072T4/tr unknown
- 2012-08-08 JP JP2014524371A patent/JP6277125B2/ja not_active Expired - Fee Related
- 2012-08-08 AU AU2012293646A patent/AU2012293646B2/en not_active Ceased
- 2012-08-08 SG SG2014009344A patent/SG2014009344A/en unknown
- 2012-08-08 CN CN201280049552.0A patent/CN104039832B/zh not_active Expired - Fee Related
- 2012-08-08 PT PT12747915T patent/PT2742068T/pt unknown
- 2012-08-08 HR HRP20190988TT patent/HRP20190988T1/hr unknown
- 2012-08-08 AR ARP120102895A patent/AR087485A1/es unknown
- 2012-08-08 HK HK15101305.1A patent/HK1200852A1/xx unknown
- 2012-08-08 WO PCT/EP2012/065505 patent/WO2013020995A1/en not_active Ceased
- 2012-08-08 KR KR1020147006274A patent/KR101947758B1/ko not_active Expired - Fee Related
- 2012-08-08 CA CA2843921A patent/CA2843921A1/en not_active Abandoned
- 2012-08-08 RS RS20190807A patent/RS58986B1/sr unknown
- 2012-08-08 RU RU2014108815A patent/RU2654584C2/ru active
- 2012-08-08 ES ES12747915T patent/ES2732838T3/es active Active
- 2012-08-08 MX MX2014001313A patent/MX364425B/es active IP Right Grant
- 2012-08-08 TW TW101128575A patent/TWI707873B/zh not_active IP Right Cessation
- 2012-08-08 SM SM20190366T patent/SMT201900366T1/it unknown
- 2012-08-08 LT LTEP12747915.2T patent/LT2742068T/lt unknown
- 2012-08-08 BR BR112014002929A patent/BR112014002929A8/pt not_active Application Discontinuation
- 2012-08-08 EP EP12747915.2A patent/EP2742068B1/en active Active
- 2012-08-08 US US14/237,035 patent/US9803028B2/en active Active
-
2014
- 2014-01-28 ZA ZA2014/00665A patent/ZA201400665B/en unknown
-
2017
- 2017-09-28 US US15/719,520 patent/US20180086848A1/en not_active Abandoned
-
2019
- 2019-06-28 CY CY20191100683T patent/CY1121950T1/el unknown
-
2021
- 2021-04-13 US US17/229,837 patent/US20210238311A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087485A1 (es) | Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| AR123876A2 (es) | Composición farmacéutica de anticuerpos anti-cgrp | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| CY1121158T1 (el) | Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης | |
| NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
| PE20121516A1 (es) | Antidotos de anticoagulantes | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| CR20170026A (es) | Anticuerpos anti-tau humanizados | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| NZ726258A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| PE20142322A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| AU2013341349A8 (en) | Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules | |
| PE20121494A1 (es) | Anticuerpos anti notch-1 | |
| PE20130192A1 (es) | Anticuerpos il-25 humanizados | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| MX2016008794A (es) | Secuencias de anticuerpos especificos para e. coli. | |
| NZ594668A (en) | Humanised antibodies with anti-tumour activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |